Xintela granted 2 million SEK from Vinnova
Lund, Sweden, March 27, 2020 – Xintela has been granted 2 million SEK from Vinnova in the call for “Innovation projects in small and medium-sized companies”. The grant concerns one of the company’s cancer projects and the work to develop targeted therapies for aggressive cancers with integrin 10-binding ADCs. “This is very good news for […]
Xintela publishes positive preclinical results from equine study
Lund, Sweden, 3 February, 2020 – Xintela announces that the results from the company’s stem cell study on horses has now been published in the respected scientific journal The American Journal of Sports Medicine. The publication demonstrates that the stem cell treatment is safe and that it has a significantly positive effect on both cartilage […]
Newsletter December 2019
Newsletter December 2019 Progress on several fronts during the year 2019 was an intensive and successful year for our projects in stem cell therapy and oncology and it is now exhilarating to look back over all the progress made by the company. The following newsletter summarises how Xintela’s operations have changed during the year and […]
Positive preclinical results in Xintela’s glioblastoma project
Lund, Sweden, December 11, 2019 – Xintela AB (publ) announces positive preclinical results in the glioblastoma project. Xintela has developed function-blocking antibodies that bind to the company’s target integrin a10b1 and identified an antibody that suppresses the growth of glioblastoma tumors in a preclinical model. In order to develop targeted antibody-based therapy for the aggressive […]
Xintela publishes interim report for the third quarter
Summary of the interim report The “company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. First nine months of the year (1 Jan 2019-30 Sep 2019)· Income amounted to TSEK 3 (1,012).· Loss before tax totalled TSEK -28,081 (-17,581).· Loss per share* was SEK -0.71 (-0.58).· At 30 September 2019, the equity/assets […]
Newsletter July 2019
This newsletter was released in Swedish on the 12th of July The beautiful summer has also arrived at Xintela and our employees are now looking forward to a well-deserved break. The summer also gives me more time to think about how Xintela’s various projects have moved forward since the start and about everything exciting […]
Steady progress and Xintela is growing
Projects making steady progress and Xintela is growing Projects in both regenerative medicine and oncology are making progress and developing very positively, which has required us to hire more personnel. We are now 18 employees and five consultants in the company, and we expect to recruit additional personal before long. As a result, we have […]
Xintela publishes results from glioblastoma study
Lund, Sweden, 26 April 2019 – Xintela announces that the results of the company’s glioblastoma study have now been published in the renowned international scientific journal Cancers. The publication demonstrates and discusses that Xintela’s marker, integrin a10b1, regulates important functions of glioblastoma cells and is a potential new therapeutic target for the treatment of the […]
Peter Edman nominated as new board member
Lund, Sweden, 26 April 2019 – The Board of Xintela AB (publ) announces that Peter Edman has been nominated for election to the Board at the annual general meeting on the 27th of May 2019. Greg Batcheller, Karin Wingstrand and Sven Kili have been proposed for re-election. The proposal is supported by major shareholders of […]
Xintela appoints Sven Kili as Chief Operating Officer
Lund, Sweden, 16 April 2019 – Sven Kili, an Executive Director and the Chief Medical Officer of Xintela, extends his commitment by taking on the Chief Operating Officer (COO) role. Sven Kili is a surgeon and specialist in orthopedics and, through leading positions in pharmaceutical companies including Genzyme, Sanofi, and GSK, has many years’ experience […]
